These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Epidemiology of quinolone resistance: Europe and North and South America. Goldstein FW; Acar JF Drugs; 1995; 49 Suppl 2():36-42. PubMed ID: 8549361 [TBL] [Abstract][Full Text] [Related]
3. The epidemiology of bacterial resistance to quinolones. Acar JF; O'Brien TF; Goldstein FW; Jones RN Drugs; 1993; 45 Suppl 3():24-8. PubMed ID: 7689447 [TBL] [Abstract][Full Text] [Related]
4. Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001. Christiansen KJ; Bell JM; Turnidge JD; Jones RN Antimicrob Agents Chemother; 2004 Jun; 48(6):2049-55. PubMed ID: 15155198 [TBL] [Abstract][Full Text] [Related]
5. [Antimicrobial activity of ciprofloxacin and netilmicin compared to various antibiotics in Lome, Togo]. Dagnra AY; Prince-David M; Hounkpati A Sante; 2001; 11(1):63-6. PubMed ID: 11313234 [TBL] [Abstract][Full Text] [Related]
6. Bacterial resistance to fluoroquinolones: lessons to be learned. Ball P Infection; 1994; 22 Suppl 2():S140-7. PubMed ID: 7927833 [TBL] [Abstract][Full Text] [Related]
7. Bacterial resistance to the quinolone antimicrobial agents. Hooper DC; Wolfson JS Am J Med; 1989 Dec; 87(6C):17S-23S. PubMed ID: 2690616 [TBL] [Abstract][Full Text] [Related]
9. In vitro antimicrobial activity of fluoroquinolones against clinical isolates obtained in 1989 and 1990. Chen YC; Chang SC; Hsu LY; Hsieh WC; Luh KT J Formos Med Assoc; 1993 Dec; 92(12):1040-8. PubMed ID: 7911351 [TBL] [Abstract][Full Text] [Related]
10. Susceptibility of recent clinical isolates to temafloxacin (A-63004) and other antimicrobial agents. Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N Drugs Exp Clin Res; 1992; 18(8):311-7. PubMed ID: 1338041 [TBL] [Abstract][Full Text] [Related]
11. [Comparative activities in vitro of 4 quinolones (nalidixic acid, pefloxacin, norfloxacin, ofloxacin) on 13 bacterial species]. Rahal K Arch Inst Pasteur Alger; 1992; 58():41-84. PubMed ID: 1309146 [TBL] [Abstract][Full Text] [Related]
12. [Impact of fluoroquinolone use on multidrug-resistant bacteria emergence]. Nseir S; Ader F; Marquette CH; Durocher A Pathol Biol (Paris); 2005; 53(8-9):470-5. PubMed ID: 16176863 [TBL] [Abstract][Full Text] [Related]
13. [Evaluation of the clinical efficacy and safety of injectable quinolones in the treatment of respiratory tract infections (discussion)]. Kohno S; Watanabe A; Mikasa K; Asano K Jpn J Antibiot; 2003 Apr; 56(2):93-104. PubMed ID: 12825412 [No Abstract] [Full Text] [Related]
14. Increasing prevalence of antimicrobial resistance among organisms isolated from blood culture in a Singapore hospital. Kumarasinghe G; Chow C; Yin LH; Hong SY; Bassett DC Southeast Asian J Trop Med Public Health; 1994 Mar; 25(1):116-22. PubMed ID: 7825001 [TBL] [Abstract][Full Text] [Related]
15. Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492. Harnett SJ; Fraise AP; Andrews JM; Jevons G; Brenwald NP; Wise R J Antimicrob Chemother; 2004 May; 53(5):783-92. PubMed ID: 15056651 [TBL] [Abstract][Full Text] [Related]
16. Prevalence of fluoroquinolone resistance in Europe. Study Group 'Bacterial Resistance' of the Paul-Ehrlich-Society for Chemotherapy e. V. Kresken M; Hafner D; Mittermayer H; Verbist L; Bergogne-Bérézin E; Giamarellou H; Esposito S; van Klingeren B; Kayser FH; Reeves DS Infection; 1994; 22 Suppl 2():S90-8. PubMed ID: 7927836 [TBL] [Abstract][Full Text] [Related]